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Abstract
There is a growing number of older people living with HIV (OPLHIV). While a significant pro-
portion of this population are adults growing into old age with HIV, there are also new infec-
tions among OPLHIV. There is a lack of data describing the outcomes of OPLHIV who
commenced antiretroviral therapy (ART) after the age of 50 years in sub-Saharan Africa.
We conducted a cohort study of patients who enrolled in care at Newlands Clinic in Harare,
Zimbabwe, at ages�50 years between February 2004 and March 2020. We examined
demographic characteristics, attrition, viral suppression, immunological and clinical out-
comes. Specifically, we described prevalent and incident HIV-related communicable and
non-communicable comorbidities. We calculated frequencies, medians, interquartile ranges
(IQR), and proportions; and used Cox proportional hazards models to identify risk factors
associated with death. We included 420 (57% female) who commenced ART and were fol-
lowed up for a median of 5.6 years (IQR 2.4–9.9). Most of the men were married (n = 152/
179, 85%) whereas women were mostly widowed (n = 125/241, 51.9%). Forty per cent (n =
167) had WHO stage 3 or 4 conditions at ART baseline. Hypertension prevalence was 15%
(n = 61) at baseline, and a further 27% (n = 112) had incident hypertension during follow-up.
During follow-up, 300 (71%) were retained in care, 88 (21%) died, 17 (4%) were lost to fol-
low-up, and 15 (4%) were transferred out. Of those in care, 283 (94%) had viral loads <50
copies/ml, and 10 had viral loads >1000 copies/ml. Seven patients (1.7%) were switched to
second line ART during follow-up and none were switched to third-line. Higher baseline CD4
T-cell counts were protective against mortality (p = 0.001) while male sex (aHR: 2.29, 95%
CI: 1.21–4.33), being unmarried (aHR: 2.06, 95%CI: 1.13–3.78), and being unemployed
(aHR: 2.01, 95%CI: 1.2–3.37) were independent independent risk factors of mortality.
There was high retention in care and virologic suppression in this cohort of OPLHIV. Hyper-
tension was a common comorbidity. Being unmarried or unemployed were significant pre-
dictors of mortality highlighting the importance of sociologic factors among OPLHIV, while
better immune competence at ART commencement was protective against mortality.
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Introduction
The number of older people living with HIV (OPLHIV) above the age of 50 years continues to
grow due to the increased life expectancy of people living with HIV. In 2019, the proportion of
OPLHIV among all people living with HIV was estimated to have risen to 21% globally, from
8% in 2000 [1, 2]. Low- and middle-income countries (LMIC) have the highest numbers of
OPLHIV and this number will increase further [2]: several studies suggest that the proportion
of OPLHIV will more than double by 2030 [3–5]. This population includes both people with
chronic HIV infection from early adulthood and new infections among older adults for rea-
sons including lack of information on safe sex and a lower likelihood of protected sex, espe-
cially among older men, compared to younger people [6].
OPLHIV have been shown to have better virologic outcomes and adherence to antiretrovi-
ral therapy (ART) than younger people, but have higher mortality and slower immune recov-
ery [7–9]. Compounding the age-related thymic contraction, HIV infection affects both B-
and T-cell function leading to accelerated immunosenescence and consequently increased risk
of non-AIDS related, age associated comorbidities in elderly patients [4, 10, 11]. Management
of OPLHIV requires a multidisciplinary team approach, taking into account the onset of non-
communicable diseases, premature ageing, and an increased risk of drug-to-drug interactions
and drug toxicities due to polypharmacy [4]. Polypharmacy also complicates selection of ART
regimens and the increased chronic pill burden may lead to treatment fatigue [12]. Several
studies have shown that men have lower uptake of ART services, increased severity of HIV dis-
ease at ART initiation and higher mortality on ART in sub-Saharan Africa [13–15].
To our knowledge, there are no studies from Zimbabwe to document outcomes of ART in
OPLHIV. However, there are emerging data on ART outcomes of OPLHIV in sub-Saharan
Africa [16, 17]. With an estimated hypertension prevalence of 30%, a diabetes prevalence of
5%, and an increasing incidence of cancer in the Zimbabwean general population, it is impera-
tive to study the prevalence of these non-communicable diseases among OPLHIV [18–20]. In
addition, antiretrovirals that continue to be used in Zimbabwe such as abacavir, efavirenz,
zidovudine and lamivudine may increase the risk of cardiovascular disease [21].
In this study, we present the sex-stratified prevalence of chronic non-communicable dis-
eases, HIV viral suppression, immunological and clinical outcomes of older patients who reg-
istered for HIV management at an HIV clinic in Harare, Zimbabwe between February 2004,
and March 2020.
Methods
Study design and ethics statement
This study was conducted within the ongoing International epidemiological Databases to Eval-
uate AIDS Southern Africa (IeDEA) cohort study of patients attending the Newlands Clinic in
Harare, Zimbabwe [22, 23]. The study was approved by the Newlands Clinic Research Team
and received ethical approval from the Medical Research Council of Zimbabwe (MRCZ No.
A1336). Participants provided written informed consent.
Study setting
Newlands Clinic is a referral outpatient clinic providing comprehensive HIV care which is
supported by the Ruedi Luethy Foundation, a Swiss-based Private Voluntary Organization.
Newlands Clinic was established in February 2004 and operates under a Public-Private Part-
nership with the Ministry of Health and Child Care of Zimbabwe. Apart from providing anti-
retroviral therapy to people living with HIV, the clinic also provides, among other services,
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onsite laboratory investigations, psychosocial support, reproductive health services including
cervical cancer screening, dental services, food support, and bus fare assistance. The patient
population is predominantly from communities with high prevalence of poverty and unem-
ployment in the Greater Harare area. Further details on the clinic’s operations are provided
elsewhere [24]. Newlands Clinic is part of the Southern African region of the International epi-
demiological Databases to Evaluate AIDS Southern Africa (IeDEA), an international research
consortium of HIV observational databases that includes four regional networks in sub-Saha-
ran Africa [23].
Study procedure
We included all patients aged 50 years or more, who were ART naïve at the time of registra-
tion, and started ART at the clinic. Patients were followed from the date of ART commence-
ment until they were transferred out, lost to follow up, or died. Follow up of patients still in
care was censored on April 30, 2020. We abstracted demographic, clinical and laboratory data
from patient records stored in the clinic’s password protected electronic medical record.
Abstracted records were anonymized by removing names and assigning sequential numeric
identifiers. We defined baseline CD4 count as a CD4 count closest to the date of initiating
ART within 90 days before ART commencement. HIV viral load (VL) measurements were
available at the clinic from the year 2014 onwards. The most recent CD4 T-cell count and VL
were defined as the last measured CD4 T-cell count or viral load for each patient. CD4 T-cell
counts were measured using the CyFlow1 Counter (Flow cytometer) and CD4 easy count
kits. HIV viral loads were measured using the COBAS1 AmpliPrep/COBAS1 TaqMan1
HIV-1 Test, version 2.0.
Nurses measured blood pressure during routine clinic visits after the patient had been
seated for at least 5 minutes, with the arm supported at the level of the heart and elbow flexed
slightly. Nurses ensured the arm was not constricted by tight clothing and placed the cuff on
naked skin with the centre of the bladder over the brachial artery. Diagnosis of hypertension
was made when a patient’s systolic or diastolic blood pressure was above 140mm Hg or above
90mm Hg, respectively, on two or more days. Risk reduction of major adverse cardiovascular
events using aspirin was only provided for patients with history of myocardial infarction. Type
II diabetes mellitus was diagnosed when a patient had a random plasma glucose > 11mmol/L
or a fasting plasma glucose� 7mmol/L. We grouped all forms of chronic arthritis, excluding
gouty arthritis and reported them as arthritis.
Patients attended clinic visits at varying intervals determined by the doctors. Those with
active comorbid conditions were seen more frequently while stable patients were seen less fre-
quently. The longest interval between visits was 90 days. Patients who missed visits were fol-
lowed up by a phone call which was recorded in the clinic’s database. Patients without an
attended visit for more than 90 days were identified using a system generated report and fol-
lowed up by a phone call, or a home visit if the phone call follow-up was unsuccessful. When
the patient could not be contacted through these strategies, they would be recorded as being
lost to follow up.
We used frequencies, medians, and interquartile ranges to describe the cohort. The Wil-
coxon Rank-Sum test was used to assess differences in skewed continuous variables across cat-
egories, and ordinary least-squares regression was used to determine a change in continuous
variables over time. The square-root of CD4 T-cell counts was used to normalize the data, and
regression analysis was used to compare changes in CD4 T-cell counts for each year on ART.
The Chi-square test was used to compare categorical variables. We used Cox Proportional
Hazards models to assess risk factors of death. Potential risk factors analyzed were sex, age at
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enrollment, being married, being unemployed, having attended secondary or higher educa-
tion, year of recruitment, having a WHO clinical stage 3 or 4 condition at ART baseline, base-
line CD4 T-cell count and being hypertensive at enrollment. Potential risk factors of death
were individually analyzed in univariate analyses. We included all potentially relevant risk fac-
tors (sex, age at ART commencement, marital status, education, ART baseline WHO clinical
stage, ART commencement period, and being hypertensive) in a multivariable Cox Propor-
tional Hazards model to determine independent risk factors of death. In the multivariable
model, CD4 counts were grouped as<100 (severely immune-suppressed), 100–199 (moder-
ately immune-suppressed), and�200 (relatively immune-competent). We used Stata (version
13.1, College Station, TX, USA) for all statistical analyses.
Results
During the study period, 420 patients aged 50 years or older were enrolled into care at New-
lands Clinic, 241 (57.4%) being female. The median age at ART commencement was 55 years
(IQR: 52–59). There was no difference in ART commencement age between males and females
(p = 0.241). More men were married (n = 152, 84.9%) compared to 58 women (24.4%), while
125 (52.5%) women were widowed compared to 15 (8.4%) men. Seventy-eight (45.1%) men
were formally employed compared to 61 (26.5%) women, while 161 women (70.0%) were
unemployed compared to 75 (43.4%) men. A total of 123 men (68.7%) had secondary or ter-
tiary education compared to 126 (52.3%) women. Most patients (59.9%) were classified in
WHO clinical stage 1 or 2 at ART commencement (Table 1). Three patients had a malignancy
at the time of ART commencement.
Attrition
The 420 patients were followed up for a total of 2612 person-years. The median duration of fol-
low up was 5.6 years (IQR: 2.4–9.9). At the time of analysis (30 April 2020), 300 (71.4%)
patients were still in care. During follow-up, 88 patients died (21.0%), 17 (4.1%) were lost to
follow up, and 15 (3.6%) were transferred to other facilities (Table 2). Among those that died,
29 (33.0%) died during the first six months after ART commencement, and 38 (43.2%) during
the first year. There was no difference in proportion of males died (23.5%) compared to
females (19.1%) (p = 0.276). The median age of patients in care at the time of analysis was 63.6
years (IQR: 58.6–67.0).
Antiretroviral therapy
The median baseline CD4 at ART commencement was 158 cells/uL (IQR: 86–274). Females
had a higher median baseline CD4 count of 171 (IQR: 89–291) compared to males (median:
144 cells/uL; IQR: 79–236; p = 0.04). Overall, baseline CD4 T-cell counts increased by 11.8
cells/uL per year (95% CI: 7.9–15.6, p<0.01), but the increase among females (15.4 cells/uL per
year, 95% CI: 9.9–21.0) was higher than among males (7.0 cells/μL per year, 95% CI: 2.3–11.6)
(Fig 1). One hundred and forty-eight patients had a baseline HIV viral load with a mean ± SD
of 4.5 log copies/ml ± 1.3.
Most patients (n = 390, 92.9%) were initiated on a first-line ART regimen containing a
non-nucleoside reverse transcriptase inhibitor (NNRTI) (efavirenz or nevirapine) and two
nucleo(t)side reverse transcriptase inhibitors (NRTI). The top three starting regimens were
tenofovir + lamivudine + efavirenz, stavudine + lamivudine + nevirapine, and zidovudine
+ lamivudine + nevirapine with 124 (29.5%), 95 (22.6%), and 91 (21.7%) patients, respectively.
Overall, 178 (42.4%) patients experienced at least one treatment adverse effect. The antire-
trovirals most discontinued due to adverse events were nevirapine, stavudine, zidovudine and
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tenofovir disoproxil fumarate (TDF). The top five overall adverse effects were peripheral sen-
sory polyneuropathy comprising 46.1% (n = 82) of all adverse effects, renal toxicity (n = 26,
14.6%), lipodystrophy (n = 17, 9.6%), zidovudine induced anaemia (n = 12, 6.7%) and grade 3
or 4 liver toxicity (n = 12, 6.7%). Stavudine-induced peripheral neuropathy accounted for
34.8% of all adverse events (n = 62).
Table 1. Baseline characteristics of older people enrolling for ART at Newlands Clinic (N = 420).
Characteristic Frequency (%)‡ p-Value (chi2 test)
Female Male Total
n = 241 (57.4) n = 179 (42.6)
Age at ART commencement, median (IQR) 54 (52–59) 55 (52–60) 55 (52–59) 0.241§
Marital Status <0.001
Married 58 (24.1) 152 (84.9) 210 (50.0)
Single 26 (10.8) 4 (2.2) 30 (7.1)
Divorced 29 (12.0) 8 (4.5) 37 (8.8)
Widowed 125 (51.9) 15 (8.4) 140 (33.3)
Unknown 3 (1.2) 0 3 (0.7)
Employment Status <0.001
Formally Employed 61 (26.5) 78 (45.1) 139 (34.5)
Self-employed 3 (1.3) 11 (6.4) 14 (3.5)
Retired 5 (2.2) 9 (5.2) 14 (3.5)
Unemployed 161 (70.0) 75 (43.4) 236 (58.6)
Education 0.007
None 31 (12.9) 12 (6.7) 43 (10.2)
Primary 84 (34.9) 44 (24.6) 128 (30.5)
Secondary 89 (36.9) 86 (48.0) 175 (41.7)
Tertiary 37 (15.4) 37 (20.7) 74 (17.6)
WHO stage† 0.727
1 81 (33.9) 51 (29.1) 132 (31.9)
2 67 (28.0) 49 (28.0) 116 (28.0)
3 64 (26.8) 52 (29.7) 116 (28.0)
4 27 (11.3) 23 (13.1) 50 (12.1)
CD4 T-cell count (cells/μL), median (IQR) 0.045
Overall 171 (89–291) 144 (79–236) 158 (86–275)
2004–2010 139 (70–198) 120 (63–181) 127 (67–191)
2011–2015 221 (97–323) 181 (97–287) 199 (97–305)
2016–2020 238 (122–485) 124 (84–305) 196 (102–393)
Log viral load (copies/ml), mean± SD 4.3 ± 1.3 4.8 ± 1.3 4.5 ± 1.3 0.031₤
Comorbidities
Diabetes 8 (3.3) 9 (5.0) 17 (4.0) 0.380
Hypertension 43 (17.8) 18 (10.1) 61 (14.5) 0.025
Chronic Cardiac Failure 3 (1.2) 0 3 (0.7) -
Arthritis 1 (0.4) 2 (1.1) 3 (0.7) 0.398
Malignancies 2 (0.8) 1 (0.6) 3 (0.7) 0.744
Chronic Kidney Disease 1 (0.4) 2 (1.1) 3 (0.7) 0.398
‡Unless otherwise specified
†414 patients had a recorded baseline WHO stage
₤148 patients had baseline HIV viral load, difference calculated by t-test
§Wilcoxon Rank-Sum test
https://doi.org/10.1371/journal.pone.0253000.t001
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Overall, seven patients experienced treatment failure and were switched to second-line
ART comprising of a ritonavir boosted protease inhibitor (atazanavir or lopinavir) and two
NRTIs. None of the patients failed second line ART. Among the 300 patients in care at the
time of analysis, 283 (94.3%) had suppressed viral loads (<50 copies/ml), while 10 (3.3%) had
viral loads >1000 copies/ml and seven (2.3%) had low-level viremia (50–1000 copies/ml).
Among those with viral loads >1000 copies/ml, 5/10 had been receiving ART for less than 24
weeks. Among those who died, 28 (31.8%) had been receiving ART for less than 24 weeks.
From a median baseline CD4 T-cell count (IQR) of 158 cells/μL (86–274), median CD4
T-cell counts gradually increased from years 1–5 of follow-up to 254 cells/μL (181–399), 305
cells/μL (221–452), 348 cells/μL (249–464), 353 cells/μL (236–465), and 374 cells/μL (273–522)
(Fig 2).
Comorbidities
During follow-up, the most common incident comorbidities were hypertension, arthritis (all
types of chronic arthritis), and chronic kidney disease (CKD) with 112 (26.7%), 83 (19.8%)
and 73 (17.4%) new diagnoses, respectively (Table 3). Among the 300 patients in care at the
end of follow-up, 148 (49.3%) had a diagnosis of hypertension with more females (n = 103,
57.5%) being hypertensive than males (n = 45, 37.2%) (p = 0.003). Among patients in care,
26 (8.7%) had a most recent estimated glomerular filtration rate (eGFR) <60mL/min/1.73m2,
Table 2. Retention in care and attrition of a cohort of older people enrolling for ART at Newlands Clinic.
Status Frequency (%)
Female (n = 241) Male (n = 179) Total (N = 420)
In care 179 (74.3) 121 (67.6) 300 (71.4)
Deceased 46 (19.1) 42 (23.5) 88 (21.0)
Lost to follow up 9 (3.7) 8 (4.5) 17 (4.0)
Transferred 7 (2.9) 8 (4.5) 15 (3.6)
https://doi.org/10.1371/journal.pone.0253000.t002
Fig 1. Baseline CD4 count distribution over ART initiation years by sex (two records with CD4 count>1000 cells/
μL omitted in the graph).
https://doi.org/10.1371/journal.pone.0253000.g001
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with 22 in CKD stage 3, and four in CKD stage 4. Of these 26 patients with CKD stage 3 or 4,
20 were female. Twenty-four (5.7%) patients, mostly female (18/26) had incident malignancies.
Among females, eight were diagnosed with cervical carcinoma in situ III (stage zero cervical
cancer), and five with cervical cancer. Other cancer types among women with one patient each
were Kaposi’s sarcoma, non-Hodgkin’s lymphoma, myosarcoma, hepatoma and ocular malig-
nancy not specified. Among males, two patients had Kaposi’s sarcoma, two had multiple mye-
loma, one had cancer of the penis and another had lymphoma.
Overall, 259 (61.7%) of participants had at least one chronic non-communicable disease
(NCD) whether prevalent at baseline or diagnosed during follow-up, excluding cervical carci-
noma in situ III and vulvar intraepithelial neoplasia III. More females had NCDs (n = 163,
67.4%) than males (n = 96, 53.6%) (p< 0.004).
Chronic disease medicines
Overall, 245 (58.3%) patients were receiving at least one additional chronic disease medicine
other than ART (median = 2, IQR: 1–4). A higher proportion of females 156 (64.7%) were
receiving additional chronic disease medicines compared to males (49.7%) (p = 0.002). Sixty-
Fig 2. CD4 T-cell count distribution across follow-up time (3 outliers, 2 Year 0 and 1 Year 1, with CD4 count
>1250 cells/uL omitted from graph) (p<0.01).
https://doi.org/10.1371/journal.pone.0253000.g002
Table 3. Incident comorbidities among older patients receiving ART at Newlands Clinic (2004–2020).
Comorbid Condition Frequency (%)
Female (n = 241) Male (n = 179) Total (N = 420)
Tuberculosis 26 (10.8) 27 (15.1) 53 (12.6)
Diabetes 6 (2.5) 7 (3.9) 13 (3.1)
Hypertension 71 (29.5) 41 (22.9) 112 (26.7)
Chronic Cardiac Failure 7 (2.9) 6 (3.4) 13 (3.1)
Arthritis 58 (24.1) 25 (14.0) 83 (19.8)
Chronic Kidney Disease 42 (17.4) 31 (17.3) 73 (17.4)
Malignancy 18 (7.5) 6 (3.4) 24 (5.7)
https://doi.org/10.1371/journal.pone.0253000.t003
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eight (16.2%) patients had more than three additional chronic disease medicines, and 24
(5.7%) (16 females and 8 males) were receiving more than five. The top five most used chronic
disease medicines were the antihypertensives hydrochlorothiazide (16.1%), amlodipine
(12.6%), nifedipine (12.6%), enalapril (9.7%), and atenolol (8.9%).
Risk of death
In the univariate analysis, increasing enrolment age, unemployment, and baseline WHO status
3 or 4 (HR: 2.66 (1.72–4.12), p< 0.001) were significant predictors of death while increasing
baseline CD4 T-cell counts were protective. Low CD4 T-cell counts, male sex, being unmarried
and being unemployed were independent risk factors of death with male patients being twice
as likely to die compared with females (Table 4). Patients who initiated ART with CD4 T-cell
counts continued to have higher mortality rates throughout the follow-up period (Fig 3).
Discussion
We present the treatment outcomes of OPLHIV who enrolled into care at Newlands Clinic in
Harare, Zimbabwe, between February 2004, and April 2020. In this cohort, most patients were
severely immune suppressed at enrolment, with significant differences between males and
females in marital status, employment, and education. Hypertension was the most prevalent
baseline and incident comorbidity, disproportionately affecting women. At analysis, 71.4% of
patients were still in care, while 21% had died and only 4% had been lost to follow-up. ART
related adverse effects were common, with 42% experiencing at least one side effect. ART was
highly successful, with 94% of patients who had received ART for over six months being virally
Table 4. Analysis of risk factors of all-cause mortality among older patients receiving ART at Newlands Clinic (2004–2020).
Characteristic Hazard Ratio (95%CI) p Adjusted Hazard Ratio (95% CI) p
Sex
Female - - - -
Male 1.27 (0.84–1.93) 0.262 2.29 (1.21–4.33) 0.010
ART commencement age 1.04 (1.0–1.1) 0.076 1.03 (0.99–1.07) 0.200
Married - - - -
Unmarried 1.27 (0.83–1.93) 0.273 2.06 (1.13–3.78) 0.019
Employed - - - -
Unemployed 1.75 (1.08–2.85) 0.024 2.01 (1.2–3.37) 0.008
Highest Education
Primary or none - - - -
Secondary or tertiary 0.77 (0.51–1.18) 0.230 0.83 (0.53–1.31) 0.428
ART Period
2004–2010 - - - 0.242
2011–2015 1.20 (0.75–1.92) 0.450 1.54 (0.93–2.56)
2016–2010 0.80 (0.38–1.69) 0.558 1.09 (0.49–2.39)
Baseline CD4 T-cell count (cells/μL)
<100 - - - 0.001
100–199 0.63 (0.39–1.02) 0.058 0.72 (0.44–1.16)
�200 0.38 (0.22–0.67) 0.001 0.35 (0.19–0.63)
Prevalent Hypertension 0.59 (0.29–1.22) 0.157 0.76 (0.36–1.6) 0.464
Baseline WHO clinical stage was omitted from multivariable analysis due to collinearity with baseline CD4 T-cell count.
https://doi.org/10.1371/journal.pone.0253000.t004
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suppressed at the time of analysis. Over half of the patients (58%) received concomitant
chronic disease medicines with their ART, mostly antihypertensives. Low baseline CD4 T-cell
counts, being unmarried, being unemployed and being male were independent risk factors of
all-cause mortality.
To our knowledge, this is the first study profiling outcomes of ART among OPLHIV in
Zimbabwe. Our cohort was similar in sex distribution to other African cohorts that are com-
prised of more women than men [25–27]. Most of the women were widows in contrast to men
who were mostly married. This difference is common in sub-Saharan Africa, where widows
are less likely to remarry than widowers [28]. Older patients with HIV face a number of chal-
lenges that may affect their quality of life. Loss of partners and friends may lead to social isola-
tion, depression and poor adherence to medicines [29]. The imbalance between men and
women regarding education and employment is also reflected in this cohort, with more men
having received education and being employed compared with women.
This study spans across a long period during which the WHO recommendations on CD4
T-cell count thresholds for ART commencement changed from <200 cells/μL to<350 cells/
μL in 2010, then to<500 cells/μL in 2013, and finally “Treat-All” from 2015 [30, 31]. Neverthe-
less, the median baseline CD4 T-cell count at the start of ART only increased each year mod-
estly, with a better improvement in baseline CD4 T-cell counts among women over time
compared with males in line with findings from aggregated data from the IeDEA and the Col-
laboration of Observational HIV Epidemiological Research in Europe (COHERE) cohorts
[32]. Nevertheless, many patients still presented with severe immunodeficiency and high viral
loads (4.8 log copies/ml) across the study period [13]. This observation reinforces the call for
interventions that target men for HIV testing and ART initiation.
Retention in care of 71.4% after a median follow up time of 5.6 years (IQR: 2.4–9.9) was
comparable with that of a younger population (74.4%) at 36 months with a median age of 35
years (IQR: 28–42) in the Zimbabwe National ART Program and higher than that observed in
a Kenyan cohort study (54%) at 36 months [33, 34]. However, unlike with this larger
Fig 3. Kaplan-Meier curve showing survivor estimates by baseline CD4 T-cell categories adjusted for sex,
employment, and marital status. Increasing baseline CD4 T-cell counts were associated with lower likelihood of
failing ART (p = 0.017), whereas being male, unemployed, or unmarried were not associated with failing ART. Among
patients still in care, the number of patients with unsuppressed viral loads was too low to assess for association between
independent risk factors of death and having unsuppressed viral loads.
https://doi.org/10.1371/journal.pone.0253000.g003
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Zimbabwean study of younger patients wherein 98% of attrition was due to loss to follow-up,
74% of attrition in our cohort was due to death. Retention in care was also higher and loss to
follow-up lower than that from an aggregated analysis of data from IeDEA sites in Africa at
five years of follow-up (66% retention in care and 18.8% LTFU in point adjusted analyses)
[35]. Implementation of patient follow-up measures as employed by Newlands Clinic is more
challenging for the National Program and other facilities that have much larger cohorts under
their care.
Viral suppression was high amongst those patients in care at 94%. While there are conflict-
ing data on viral suppression and immune recovery among older patients initiating ART [4],
our cohort showed remarkable recovery during follow up with statistically significant increases
in median CD4 T-cell counts with each year on ART. Stavudine has been discontinued as an
ART option due to its high side effects profile that includes peripheral neuropathy, lipodystro-
phy, lactic acidosis and pancreatitis [36]. Peripheral sensory polyneuropathy was the most
common ART adverse effect in this study. Older age has been shown to be associated with
peripheral neuropathy in both HIV infected and uninfected people [37, 38]. Zidovudine and
tenofovir disoproxil fumarate are still in use in LMIC and clinicians should continue to moni-
tor elderly patients for adverse effects while on these medicines.
Prevalence of hypertension was high, as was its incidence during follow-up. This is consis-
tent with previously published Zimbabwean data that estimated hypertension prevalence at
30% (95% CI: 19% - 42%) in the general population [18]. The prevalence of hypertension in
this cohort at the end of follow-up (49.3%) was much higher than that of the general popula-
tion, with a higher burden among females. Consequently, antihypertensives comprised the
biggest proportion of additional medicines used by the participants in our cohort. Close to a
fifth of patients developed CKD. This is also consistent with existing knowledge that the risk of
CKD is high in PLHIV and increases with age [39]. Earlier studies in South Africa have also
shown a high burden of hypertension, stroke, diabetes and obesity among OPLHIV [40].
Overall, women had a higher burden of NCDs compared with men. There are mixed findings
on the distribution of NCDs among people living with HIV between men and women [41, 42].
Still, our findings are limited by our study design which used routinely collected clinical data
and could not comprehensively assess for all important NCDs. Nevertheless, our findings rein-
force the need for continuous hypertension and renal monitoring among OPLHIV.
Lower CD4 T-cell counts at ART commencement, being male, unmarried, or unemployed
were independent risk factors of all-cause mortality in this cohort. Advanced immunosuppres-
sion, depicted by CD4 T-cell counts below 100 cells/μL, is an indicator of late ART initiation
or presentation to care and is associated with high mortality across all age groups [33, 34, 43].
Male patients were twice as likely to die compared to women in our cohort in line with existing
literature [13]. This difference could be explained by the higher viral loads and lower CD4 T-
cell counts among male patients at ART initiation which are known to be associated with
worse outcomes on ART [44]. Despite women being disproportionately affected by adverse
social factors as well as hypertension, male patients still had a higher mortality risk in keeping
with global general population trends [45]. The observed trend of persistently higher mortality
throughout follow-up among people who initiated ART with lower CD4 T-cell counts and the
lower baseline CD4 T-cell counts among men affirms the need for a shift in the HIV treatment
strategy to improve the ART outcomes observed in men starting with enhanced enrolment
strategies [15, 46]. The higher risk of mortality among unmarried people that we observed
may be due to several factors including the effect of social relationships, including marriage,
on mortality as well as a lack of treatment support [47, 48]. Unemployment was a significant
risk factor of death in our cohort. Although employment alone is not a comprehensive wealth
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index indicator, this finding is in line with a study conducted in Manicaland, Zimbabwe where
a high wealth index was protective against both HIV infection and HIV-related mortality [49].
The strength of this study is the high quality of the data, which is ensured by routine data
quality checks conducted by clinicians and a data quality manager. However, our study was
based on routinely collected data, and we note some of the limitations associated with this
method. HIV viral load monitoring was introduced in 2014, and analysis of viral suppression
outcomes before this period could not be done. Cause of death information was not available
in the records of deceased patients presenting a limitation in our analysis of risk factors of
mortality. Furthermore, our study spans a 16-year period during which mortality risk factors
may have evolved significantly. The outcomes of this cohort may not be generalizable to other
facilities that have a less comprehensive approach to ART management than provided by New-
lands Clinic or have much higher patient to clinician ratios. However, these outcomes show
what can be achieved in the care of OPLHIV.
Conclusion
Our study showed high HIV treatment success among OPLHIV, but with a high burden of
hypertension, particularly among women. Low CD4 T-cell counts, male sex, being unmarried
and being unemployed were independent predictors of mortality, highlighting the importance
of social and socioeconomic factors in addition to the well described early ART for longevity
among OPLHIV. We recommend psychosocial support programs to augment the “treat-all”
approach aimed at providing ART early before severe immune suppression to improve longev-
ity among OPLHIV.
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